PE20010917A1 - CRYSTALLINE FORM OF EPLERENONE SHOWING AN INCREASE IN DISSOLUTION RATE - Google Patents
CRYSTALLINE FORM OF EPLERENONE SHOWING AN INCREASE IN DISSOLUTION RATEInfo
- Publication number
- PE20010917A1 PE20010917A1 PE2000001300A PE0013002000A PE20010917A1 PE 20010917 A1 PE20010917 A1 PE 20010917A1 PE 2000001300 A PE2000001300 A PE 2000001300A PE 0013002000 A PE0013002000 A PE 0013002000A PE 20010917 A1 PE20010917 A1 PE 20010917A1
- Authority
- PE
- Peru
- Prior art keywords
- eplerenone
- refers
- crystal
- dicarboxylate
- crystaline
- Prior art date
Links
- JUKPWJGBANNWMW-VWBFHTRKSA-N eplerenone Chemical compound C([C@@H]1[C@]2(C)C[C@H]3O[C@]33[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)C(=O)OC)C[C@@]21CCC(=O)O1 JUKPWJGBANNWMW-VWBFHTRKSA-N 0.000 title abstract 9
- 229960001208 eplerenone Drugs 0.000 title abstract 8
- 238000004090 dissolution Methods 0.000 title abstract 2
- 239000013078 crystal Substances 0.000 abstract 3
- 238000002425 crystallisation Methods 0.000 abstract 2
- 230000008025 crystallization Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- XNSDIIWFWKXZBT-PGBIDFRPSA-N 3-[(1R,2S,10R,11S,14S,15S)-14-hydroxy-9-methoxycarbonyl-2,15-dimethyl-5-oxo-18-oxapentacyclo[8.8.0.01,17.02,7.011,15]octadec-6-en-14-yl]propanoic acid Chemical compound C1[C@]2(C)[C@](CCC(O)=O)(O)CC[C@H]2[C@@H]2C(C(=O)OC)CC3=CC(=O)CC[C@]3(C)[C@@]32OC31 XNSDIIWFWKXZBT-PGBIDFRPSA-N 0.000 abstract 1
- 102000003979 Mineralocorticoid Receptors Human genes 0.000 abstract 1
- 108090000375 Mineralocorticoid Receptors Proteins 0.000 abstract 1
- 238000002441 X-ray diffraction Methods 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000002844 melting Methods 0.000 abstract 1
- 230000008018 melting Effects 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
- C07J71/001—Oxiranes
- C07J71/0015—Oxiranes at position 9(11)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
SE REFIERE A LA FORMA H DE EPLERENONA (METIL HIDROGENO 9,11-EPOXI-17-HIDROXI-3-OXOPREGN-4-ENE-7,21-DICARBOXILATO, g-LACTONA) QUE TIENE UNA DISOLUCION RAPIDA EN MEDIO ACUOSO Y SE CARACTERIZA POR PRESENTARSE EN FORMA DE CRISTAL ORTOROMBICO; PATRON DE DIFRACCION DE RAYOS X; PUNTO DE FUSION DE 247°C A 251°C; TAMANO DE PARTICULAS D90 INFERIOR A 400µm; TAMBIEN SE REFIERE A UNA DROGA QUE COMPRENDE DE 90% A 100% DE LA FORMA H Y EL RESTO CONSISTE DE EPLERENONA CRISTALINA FORMA L CON UN SISTEMA DE CRISTALES MONOCLINICOS; FORMA SOLVATADA DE EPLERENONA CRISTALINA, EPLERENONA AMORFA; UTILIZANDOSE DE 10mg A 1000mg. TAMBIEN SE REFIERE A i)UN METODO PARA PREPARAR LA FORMA H; ii)EPLERENONA AMORFA LIBRE DE LA FORMA CRISTALINA; iii)METODO PARA PROMOVER LA CRISTALIZACION DE LA FORMA H DE EPLERENONA QUE COMPRENDE BANAR LA SOLUCION ANTES DE LA CRISTALIZACION CON COMPUESTOS DE BANADO QUE EN FORMA SUSTANCIAL SON CRISTALOGRAFICAMENTE ISOESTRUCTURAL CON LA EPLERENONA FORMA H COMO 7-METILHIDROGENO 4O,5O,9O; 11O-DIEPOXIDO-17-HIDROXI-3-OXO-17O-PREGNAN-7O,21-DICARBOXILATO. LA EPLERENONA ES UN ANTAGONISTA DEL RECEPTOR DE ALDOSTERONAIT REFERS TO THE H FORM OF EPLERENONE (METHYL HYDROGEN 9,11-EPOXY-17-HYDROXY-3-OXOPREGN-4-ENE-7,21-DICARBOXYLATE, g-LACTONE) WHICH HAS A RAPID DISSOLUTION IN A WATERY MEDIUM AND IS CHARACTERIZED FOR PRESENTING IN THE FORM OF ORTHOROMBIC CRYSTAL; X-RAY DIFFRACTION PATTERN; MELTING POINT OF 247 ° C TO 251 ° C; PARTICLE SIZE D90 LESS THAN 400µm; IT ALSO REFERS TO A DRUG THAT INCLUDES 90% TO 100% OF FORM H AND THE REST CONSISTS OF EPLERENONE CRYSTALINE FORM L WITH A MONOCLINIC CRYSTAL SYSTEM; SOLVATED FORM OF EPLERENONE CRYSTALINE, EPLERENONE AMORPHOUS; USING FROM 10mg TO 1000mg. IT ALSO REFERS TO i) A METHOD FOR PREPARING FORM H; ii) EPLERENONE AMORPHOUS FREE OF THE CRYSTAL FORM; iii) METHOD TO PROMOTE THE CRYSTALLIZATION OF THE FORM H OF EPLERENONE THAT INCLUDES BANAR THE SOLUTION BEFORE CRYSTALLIZATION WITH BATTERY COMPOUNDS THAT IN A SUBSTANTIAL FORM ARE CRYSTALOGRAPHICALLY ISOESTRUCTURAL WITH THE EPLERENONE FORM HIDROEN, 5-METHYLHYL 9; 11O-DIEPOXIDO-17-HYDROXY-3-OXO-17O-PREGNAN-7O, 21-DICARBOXYLATE. EPLERENONE IS AN ALDOSTERONE RECEPTOR ANTAGONIST
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16963999P | 1999-12-08 | 1999-12-08 | |
| US16980799P | 1999-12-08 | 1999-12-08 | |
| US16968299P | 1999-12-08 | 1999-12-08 | |
| US16960899P | 1999-12-08 | 1999-12-08 | |
| US16955699P | 1999-12-08 | 1999-12-08 | |
| US16969099P | 1999-12-08 | 1999-12-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20010917A1 true PE20010917A1 (en) | 2001-09-10 |
Family
ID=27558585
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2000001300A PE20010917A1 (en) | 1999-12-08 | 2000-12-06 | CRYSTALLINE FORM OF EPLERENONE SHOWING AN INCREASE IN DISSOLUTION RATE |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP1177204A2 (en) |
| JP (1) | JP2003516414A (en) |
| KR (1) | KR100607923B1 (en) |
| CN (2) | CN1152886C (en) |
| AU (1) | AU784946B2 (en) |
| BR (1) | BR0008057A (en) |
| CA (1) | CA2362669A1 (en) |
| CO (1) | CO5280211A1 (en) |
| EA (1) | EA007934B1 (en) |
| HU (1) | HUP0203032A3 (en) |
| IL (3) | IL144764A0 (en) |
| MX (1) | MXPA01008056A (en) |
| MY (1) | MY131878A (en) |
| NO (1) | NO20013856L (en) |
| NZ (2) | NZ513961A (en) |
| PE (1) | PE20010917A1 (en) |
| WO (1) | WO2001042272A2 (en) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2479383A1 (en) * | 2002-03-20 | 2003-10-02 | Pharmacia Corporation | Storage stable eplerenone formulation |
| US7235655B2 (en) | 2002-03-22 | 2007-06-26 | Pharmacia & Upjohn Company | Processes to prepare eplerenone |
| CA2582496A1 (en) | 2007-03-20 | 2008-09-20 | Apotex Pharmachem Inc. | Improved process for the preparation and purification of eplerenone |
| CA2796307A1 (en) | 2010-05-10 | 2011-11-17 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and compositions for the treatment of fluid accumulation in and/ or under the retina |
| EP2582365B1 (en) | 2010-06-16 | 2019-03-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Compositions for stimulating reepithelialisation during wound healing |
| WO2017064121A1 (en) | 2015-10-13 | 2017-04-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of choroidal neovascularisation |
| GB201609607D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts |
| US20190262363A1 (en) | 2016-07-26 | 2019-08-29 | INSERM (Institut National de la Santé et de la Recherche Médicale | Antagonist of mineralocorticoid receptor for the treatment of osteoarthritis |
| GB201719881D0 (en) | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of plasma kallikrein inhibitor and salts thereof |
| CN108059648A (en) * | 2017-12-30 | 2018-05-22 | 合肥久诺医药科技有限公司 | A kind of eplerenone solvate and preparation method thereof |
| EP4395785A1 (en) | 2021-08-31 | 2024-07-10 | Inserm (Institut National de la Santé et de la Recherche Scientifique) | Methods for the treatment of ocular rosacea |
| WO2023204729A1 (en) * | 2022-04-19 | 2023-10-26 | Общество с ограниченной ответственностью "Гелеспон" | Pharmaceutical compositions based on a novel substance of 4-[2-(1н-imidazol-4-yl)-ethylcarbamoyl]-butanoic acid and method for producing said substance |
| CN120754115A (en) * | 2025-05-23 | 2025-10-10 | 远大医药（中国）有限公司 | Eplerenone-containing composition, pharmaceutical preparation, preparation method and use thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4559332A (en) * | 1983-04-13 | 1985-12-17 | Ciba Geigy Corporation | 20-Spiroxanes and analogues having an open ring E, processes for their manufacture, and pharmaceutical preparations thereof |
| BR9714510A (en) * | 1996-12-11 | 2000-11-28 | Searle & Co | Process and preparation of 9,11-epoxy steroids and useful intermediates |
| DK1382351T3 (en) * | 1999-03-05 | 2006-01-23 | Searle Llc | Combination therapy with angiotensin converting enzyme inhibitor and epoxy steroidal aldosterone antagonist to treat cardiovascular disease |
-
2000
- 2000-12-04 NZ NZ513961A patent/NZ513961A/en not_active IP Right Cessation
- 2000-12-04 EA EA200100871A patent/EA007934B1/en not_active IP Right Cessation
- 2000-12-04 BR BR0008057-8A patent/BR0008057A/en not_active IP Right Cessation
- 2000-12-04 EP EP00983781A patent/EP1177204A2/en not_active Withdrawn
- 2000-12-04 AU AU20492/01A patent/AU784946B2/en not_active Ceased
- 2000-12-04 JP JP2001543569A patent/JP2003516414A/en not_active Withdrawn
- 2000-12-04 CA CA002362669A patent/CA2362669A1/en not_active Abandoned
- 2000-12-04 MX MXPA01008056A patent/MXPA01008056A/en not_active Application Discontinuation
- 2000-12-04 IL IL14476400A patent/IL144764A0/en active IP Right Grant
- 2000-12-04 NZ NZ530028A patent/NZ530028A/en not_active IP Right Cessation
- 2000-12-04 HU HU0203032A patent/HUP0203032A3/en unknown
- 2000-12-04 CN CNB008057788A patent/CN1152886C/en not_active Expired - Fee Related
- 2000-12-04 CN CNA2004100368081A patent/CN1557833A/en active Pending
- 2000-12-04 WO PCT/US2000/032416 patent/WO2001042272A2/en not_active Ceased
- 2000-12-04 KR KR1020017010043A patent/KR100607923B1/en not_active Expired - Fee Related
- 2000-12-06 MY MYPI20005734A patent/MY131878A/en unknown
- 2000-12-06 PE PE2000001300A patent/PE20010917A1/en not_active Application Discontinuation
- 2000-12-11 CO CO00094075A patent/CO5280211A1/en not_active Application Discontinuation
-
2001
- 2001-08-06 IL IL144764A patent/IL144764A/en not_active IP Right Cessation
- 2001-08-08 NO NO20013856A patent/NO20013856L/en not_active Application Discontinuation
-
2006
- 2006-06-22 IL IL176511A patent/IL176511A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0203032A2 (en) | 2002-12-28 |
| IL176511A (en) | 2007-08-19 |
| BR0008057A (en) | 2002-04-23 |
| HUP0203032A3 (en) | 2003-04-28 |
| NZ530028A (en) | 2005-08-26 |
| JP2003516414A (en) | 2003-05-13 |
| CA2362669A1 (en) | 2001-06-14 |
| NO20013856D0 (en) | 2001-08-08 |
| HK1050536A1 (en) | 2003-06-27 |
| AU784946B2 (en) | 2006-08-03 |
| CN1377365A (en) | 2002-10-30 |
| NZ513961A (en) | 2004-02-27 |
| MXPA01008056A (en) | 2003-07-21 |
| KR100607923B1 (en) | 2006-08-04 |
| CN1557833A (en) | 2004-12-29 |
| IL144764A0 (en) | 2002-06-30 |
| WO2001042272A2 (en) | 2001-06-14 |
| EA007934B1 (en) | 2007-02-27 |
| EP1177204A2 (en) | 2002-02-06 |
| EA200100871A1 (en) | 2002-04-25 |
| MY131878A (en) | 2007-09-28 |
| NO20013856L (en) | 2001-10-08 |
| KR20010112261A (en) | 2001-12-20 |
| AU2049201A (en) | 2001-06-18 |
| CN1152886C (en) | 2004-06-09 |
| CO5280211A1 (en) | 2003-05-30 |
| IL144764A (en) | 2007-08-19 |
| WO2001042272A3 (en) | 2001-11-29 |
| WO2001042272A9 (en) | 2002-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20010917A1 (en) | CRYSTALLINE FORM OF EPLERENONE SHOWING AN INCREASE IN DISSOLUTION RATE | |
| CO5770096A1 (en) | BABY CRYSTAL FORM OF IVABRADINE CHLORHITRATE, ITS PREPARATION PROCEDURE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
| CO5770098A1 (en) | BETA-D CRYSTAL FORM OF IVABRADINE CHLORHITRATE, ITS PREPARATION PROCEDURE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
| UY25404A1 (en) | PAROCEDURE TO CARRY OUT A SOLID STATE CRYSTALIZATION OF AN ALLOTROPIC MOLECULAR ORGANIC COMPOUND IN PARTICLES OF DEFINED SIZE AND SHAPES | |
| CO5840253A1 (en) | CRYSTALINE DELTA D FORM OF IVABRADINE CHLORHYDRATE, ITS PREPARATION PROCEDURE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
| CO5770095A1 (en) | GAMMA-D CRYSTAL FORM OF IVABRADINE CHLORHITRATE, ITS PREPARATION PROCEDURE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
| AR079473A2 (en) | CRYSTAL COMPOUND OF BENZIMIDAZOL PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND METHOD FOR THE MANUFACTURE OF SUCH COMPOSITION | |
| PH12012501146A1 (en) | Crystalline forms of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl]-1-methyl-urea and salts thereof | |
| CO5670355A2 (en) | CRYSTAL FORM OF CALCIUM ACID SALT OF BIS [(E) -7- [4- (4-FLUOROPHENYL) -6-ISOPROPIL-2- [METHYL (METILSULFONIL) AMINO] PIRIMIDIN-5-IL] (3R, 5S) - 3,5-DIHYDROXIHEPT-6-ENOICO | |
| PE20010911A1 (en) | SOLID STATE FORM OF CELECOXIB THAT HAS IMPROVED BIODAVAILABILITY | |
| PE20010918A1 (en) | CRYSTAL FORM OF EPLERENONE | |
| PE20131394A1 (en) | MONOHYDRATE OF AZA-ADAMANTAN DERIVATIVES | |
| ATE305008T1 (en) | GONADOTROPIN RELEASING HORMONE RECEPTOR ANTAGONISTS AND THEIR RELATED USES | |
| JP2012131697A (en) | Immobilizing method of carbon dioxide | |
| DE60008960D1 (en) | II-VI Type-P compound semiconductor crystals, process for growing them and their use in semiconductor devices | |
| BR0002451A (en) | Method for merging information transferred by a wireless communication system | |
| DE602004011632D1 (en) | PRE-FILLED CRYSTALLIZATION CARRIER AND THEIR PRODUCTION AND USE | |
| PE20020942A1 (en) | AQUEOUS HERBICIDE COMPOSITION CONTAINING ALGINATE AS A GELLING AGENT | |
| JP2008176935A (en) | Steel pipe pole | |
| EA200701649A1 (en) | ENERGY ISOLATION PROCESS AND DEVICE FOR ITS IMPLEMENTATION | |
| AR017052A1 (en) | DERIVATIVES OF CARBOXYL ACID AND ITS USE TO PREPARE MEDICINES. | |
| CN204199780U (en) | A kind of life Noah's ark for rescuing on the spot after calamity | |
| CO4940415A1 (en) | CHEMICAL COMPOUND | |
| Carveni et al. | La Salsa e la Gurna di Fondachello: evoluzione di un vulcano di fango e di uno stagno costiero all’estrema periferia nord-orientale dell’edificio vulcanico etneo (Sicilia) | |
| Mehmood | Ionothermal Template Transformation as a Sustainable Route Towards Carbon Electrodes in Energy Storage and Conversion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |